公开(公告)号：EP1857818A1

公开(公告)日：2007-11-21

申请号：EP06009954.6

申请日：2006-05-15

申请人： DIGILAB BioVisioN GmbH

发明人： Budde, Petra, Dr. ,  Zucht, Hans-Dieter, Dr. ,  Tammen, Harald, Dr. ,  Hess, Rüdiger, Dr. ,  Menzel, Christoph, Dr

IPC分类号： G01N33/68 ,  C07K14/765 ,  C07K14/575 ,  A61P3/10

CPC分类号： C07K14/765 ,  G01N33/6893 ,  G01N2800/042

摘要： The present invention is in the field of diagnostics and therapeutics. Specifically, the present invention provides methods for diagnosis and therapy of diseases and conditions associated with oxidative stress such as Type 2 diabetes, hyperglycaemia, preeclampsia, aging, etc. Furthermore the invention provides peptides, binding agents recognizing said peptides, diagnostic assay kits, and compositions suitable for medical purposes. The peptides of the invention are characterized by a C-terminal, non-enzymatic originated amide or by a nitric oxide binding site. The peptides of the invention are suitable as biomarker or as therapeutic substances capable to function as nitric oxide delivery vehicles.

摘要翻译： 本发明是在诊断和治疗的领域。 具体而言，本发明提供了用于治疗与氧化应激相关的疾病和病症的诊断和治疗的方法：例如2型糖尿病，高血糖症，先兆子痫，老化等进一步，本发明提供的肽，结合剂识别所述肽，诊断测定试剂盒和 适合用于医疗目的的组合物。 本发明的肽通过C末端为特征的，非酶源自酰胺或由一氧化氮结合位点。 本发明的肽是适合作为生物标志物或能够用作一氧化氮输送车作为治疗物质。

公开(公告)号：EP1742059A1

公开(公告)日：2007-01-10

申请号：EP04029171.8

申请日：2004-12-09

申请人： DIGILAB BioVisioN GmbH

发明人： Tammen, Herald, Dr. ,  Pich, Andreas, Dr. ,  Traub, Frank, Dr. ,  Hess, Rüdiger, Dr. ,  Lamping, Norbert, Dr. ,  Schorn, Karl, Dr. ,  Kreipe, Hans, Prof. Dr.

IPC分类号： G01N33/574 ,  C07K14/575 ,  C07K16/26 ,  C12N15/00 ,  C12N5/00 ,  A61P35/00

CPC分类号： G01N33/57449 ,  G01N33/57415 ,  G01N33/57434 ,  G01N2333/5759 ,  G01N2800/52

摘要： Several types of cancer cells are treated with specialized therapies, as they have specific properties such as steroid-dependant, especially estradiol-dependant growth. Breast cancer and colon cancer cells often depend to some extend on estradiol-mediated growth signals. Therefore, especially breast cancer patients are routinely tested for the presence of estradiol receptors by immune histology. If the estradiol receptor is present usually an anti-estradiol therapy is used to eradicate the tumour and to prevent rezidives. However to a certain extend this therapy does not work and it would be an advantage to know this as early as possible, thereby not to loose any time with wrong therapy concepts. Therefore a better predictive marker to diagnose steroid-dependant cancer cells is necessary, which is provided by this invention. Prothymosin alpha (PTA) can be measured in tissue samples and plasma of breast cancer and colon cancer patients and indicates, whether the estradiol pathway is functional and consequently whether anti-estradiol therapy may be successful. PTA can be a surrogate for estradiol receptor detection by immune histology, can be a marker to monitor resistance of cancer cells towards anti-estradiol therapy and has the advantage to be determined from easily accessible patient samples such as serum or plasma. Claimed are PTA peptides and nucleic acids, binding agents therefore, test kits and diagnostic and therapeutic methods and compositions.

摘要翻译： 用专门的疗法治疗几种类型的癌细胞，因为它们具有特定的性质，例如类固醇依赖性，特别是雌二醇依赖性生长。 乳腺癌和结肠癌细胞通常依赖于雌二醇介导的生长信号。 因此，特别是乳腺癌患者通过免疫组织学常规测试雌二醇受体的存在。 如果雌二醇受体通常存在，则使用抗雌二醇治疗来消除肿瘤并防止溃疡。 然而，在某种程度上，这种治疗方法不起作用，并且尽可能早地知道这一点是有利的，因此不会因为错误的治疗概念而放松任何时间。 因此，本发明提供了一种用于诊断类固醇依赖性癌细胞的更好的预测标记。 可以在组织样本和乳腺癌和结肠癌患者的血浆中测量孕激素α（PTA），并指示雌二醇途径是否功能，从而抗雌二醇治疗是否可以成功。 PTA可以作为通过免疫组织学检测雌二醇受体的替代物，可以作为监测癌细胞抵抗抗雌二醇治疗的抗性的标志物，并具有从容易获得的患者样品如血清或血浆中确定的优点。 据称是PTA肽和核酸，因此结合剂，测试试剂盒以及诊断和治疗方法和组合物。